Form 13-F position report

REVOLUTION MEDICINES INC

Reported by EAM Investors LLC

RVMD CUSIP 76155X100 Manager CIK 0001510989

Reported 44,332 shares, down 5,025 (10.2%) from the prior quarter.

Reported value -1.6%; share count -10.2% vs. the prior quarter.

Reduced
% of reported 13F value 0.94% This manager · Q3 2026
Shares 44,332 Quarter-end amount reported
Reported value $9,099,586 Fair value at quarter end
Consecutive quarters held 4 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2024-06-30 3920703
2024-09-30 3229374
2024-12-31 0
2025-12-31 5116397
2026-03-31 4874365
2026-06-30 9243579
2026-09-30 9099586

Quarterly position history

How this manager's reported quarter-end position changed over time.

7 quarters
Quarterly reported position history for REVOLUTION MEDICINES INC held by EAM Investors LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Reduced 44,332 -5,025 (-10.2%) 0.94% $9,099,586 2026-11-16
Q2 2026 Reduced 49,357 -765 (-1.5%) 0.82% $9,243,579 2026-08-13
Q1 2026 Reduced 50,122 -14,114 (-22.0%) 0.56% $4,874,365 2026-05-13
Q4 2025 New 64,236 +64,236 (0.0%) 0.57% $5,116,397 2026-02-12
Q4 2024 Reduced 0 -71,210 (-100.0%) 0 $0 2025-02-13
Q3 2024 Reduced 71,210 -29,813 (-29.5%) 0.48% $3,229,374 2024-11-13
Q2 2024 New 101,023 +101,023 (0.0%) 0.64% $3,920,703 2024-08-12

Who else reported the position

828 managers reported REVOLUTION MEDICINES INC for Q3 2026.

Managers reporting REVOLUTION MEDICINES INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
FMR LLC Added 15,397,714 +3,197,292 0.14% $3,160,534,467 27 qtrs
BlackRock Inc Added 13,857,324 +161,534 0.04% $2,844,354,468 9 qtrs
FARALLON CAPITAL MANAGEMENT LLC Reduced 13,418,796 -132,000 11.87% $2,754,342,067 23 qtrs
BAKER BROS ADVISORS LP Reduced 10,637,318 -806,039 10.38% $2,183,415,893 23 qtrs
Darwin Global Management Ltd Unchanged 10,629,822 0 54.66% $2,181,877,264 3 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Added 9,149,534 +60,873 0.04% $1,878,033,349 3 qtrs
VANGUARD PORTFOLIO MANAGEMENT LLC Reduced 8,157,073 -137,782 0.08% $1,674,320,804 3 qtrs
Nextech Invest Ltd Unchanged 7,601,087 0 69.89% $1,560,199,118 7 qtrs
JANUS HENDERSON GROUP PLC Reduced 7,573,603 -2,192,893 0.66% $1,555,023,854 1 qtr
Paradigm Biocapital Advisors LP Reduced 6,219,323 -142,000 25.38% $1,276,578,239 11 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 16, 2026
Filing type
13F-HR
Position type
Common Stock

Voting authority reported

Sole
9,511
Shared
0
None
34,821

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.